Vimarsana
Biggest News Aggregation in the World

Brian Abrahams News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Brian Abrahams. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Brian Abrahams Today - Breaking & Trending Today

CSPAN Newsmakers March 1, 2015 - Vimarsana News

CSPAN Newsmakers March 1, 2015

It might actually enable it. On tuesday, when you visited the house, you are asked your representative to sign a letter, coauthored by congressman reiss and ingle. It lays out the elements of a good deal. It reiterates the role of congress and highlights irans destructive regional activities. You will voice your concern and ask members to be ready to reject a bad deal. [applause] this brings us to our third message for the hill. The importance of congresss role on a matter as critical as the Iranian Nuclear issue. Congress must have a say. Congress has played a vital role in bringing iran to t...

FDA analysis raises no major concerns about Eli Lilly Alzheimer's drug - Vimarsana News

FDA analysis raises no major concerns about Eli Lilly Alzheimer's drug

An FDA analysis of trial data for Eli Lilly's experimental Alzheimer's drug donanemab released on Thursday revealed no red flags, but raised questions about safety of the treatment for patients with early-stage disease.

Source: ksl.com
European Commission, in 'unprecedented' move, declines to revoke approval of PTC Duchenne drug - Vimarsana News

European Commission, in 'unprecedented' move, declines to revoke approval of PTC Duchenne drug

BioPharma

Galapagos NV (NASDAQ:GLPG) Q1 2024 Earnings Call Transcript - Vimarsana News

Galapagos NV (NASDAQ:GLPG) Q1 2024 Earnings Call Transcript

Sofie Van Gijsel: Welcome all to the audio webcast of Galapagos' Q1 2024 Results. I'm Sofie Van Gijsel, Investor Relations representing the reporting team at Galapagos.

AstraZeneca, Daiichi look to broaden Enhertu use again with new study data - Vimarsana News

AstraZeneca, Daiichi look to broaden Enhertu use again with new study data

BioPharma